Abstract 228P
Background
Cabozantinib, a novel TKI is an oral multitargeted inhibitor of VEGFR, MET and AXL kinases. The CABOSUN trial established the superiority of cabozantinib over sunitinib in newly diagnosed renal cell carcinoma (RCC) of intermediate or poor risk. Currently it is used as a single agent (intermediate risk) or in combination with nivolumab (intermediate and poor risk). However, data is lacking with respect to the real-world use patterns of cabozantinib.
Methods
In this study, we explored the use of single agent cabozantinib in advanced RCC in terms of dosing, effectiveness, tolerability, and toxicity profiles. This was a single center retrospective observational study from All India Institute of Medical Sciences, New Delhi, India. Data was collected retrospectively from prospectively maintained database. All eligible patients were aged 18 years or older, had measurable lesions, available case records, received at least 2 months of the drug and were evaluable for response.
Results
In total, 70 patients were identified with a median age of 53 years (interquartile, 47-65 years). Majority were males (81.4%). The different histologies were (clear cell 77.1%, papillary 11.4%, and translocation related 5.7%). 54.3% had prior nephrectomy. Majority had an IMDC score as intermediate (61.4%), followed by favorable (22.9%). Most common site of metastases was lung (60%) followed by bone (32.9%). Cabozantinib was started as the first line TKI in 60% (42/70), as 2nd line in 74.2% (23/31). Starting dose was 60mg in 27%, and 40mg in 73%. Dose reductions of cabozantinib were seen in 40.7% in 1st line, and 58.2% in 2nd line. Re escalation was done in 24.2%. Most common reason for dose reduction was diarrhea (64.7%). 35.7% had a partial response and 2.9% had a CR. ORR for overall population was 39.1%. Overall median PFS was 7.2 months. Most common adverse events were diarrhea in 42.7%, Hand-Foot skin reaction in 27.6%, mucositis in 17.8% and hepatotoxicity in 5.1%.
Conclusions
This study showed the practical dosing strategies and modifications of cabozantinib in the real world setting and how it differed from actual literature. We hope this study would help oncologists make better informed decisions while prescribing cabozantinib in advanced RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract